• Home
  •  / BioSpecifics Technologies

BioSpecifics Technologies

OverviewSuggest Edit

BioSpecifics Technologies is a biopharmaceutical company which engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company offers injectable collagenase in Canada and Australia, as well as in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The Company is also involved in the development of other clinical indications for which collagenase injection has been tested.

TypePublic
Founded1957
HQLynbrook, NY, USMap
Websitebiospecifics.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)7(+40%)
Revenue (FY, 2019)$38.2 M(+16%)
Share Price (Dec 2020)$88.5
Cybersecurity ratingAMore

Key People/Management at BioSpecifics Technologies

Joseph Truitt

Joseph Truitt

Chief Executive Officer & Director
Mike Sherman

Mike Sherman

Director & Audit Committee Financial Expert
Alex Monteith

Alex Monteith

Chief Business Officer
Patrick Hutchison

Patrick Hutchison

Chief Financial Officer
Show more

BioSpecifics Technologies Office Locations

BioSpecifics Technologies has offices in Lynbrook and Wilmington
Lynbrook, NY, US (HQ)
35 Wilbur St
Wilmington, DE, US
2 Righter Pkwy #200
Show all (2)

BioSpecifics Technologies Financials and Metrics

BioSpecifics Technologies Revenue

BioSpecifics Technologies's revenue was reported to be $38.19 m in FY, 2019
USD

Revenue (Q2, 2020)

3.9m

Net income (Q2, 2020)

115.8k

EBIT (Q2, 2020)

(250.9k)

Market capitalization (17-Dec-2020)

650.2m

Closing stock price (17-Dec-2020)

88.5

Cash (30-Jun-2020)

16.9m

EV

633.6m
BioSpecifics Technologies's current market capitalization is $650.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

11.4m11.1m14.5m14.1m22.8m26.3m27.4m33.0m38.2m

Revenue growth, %

15%

General and administrative expense

5.2m4.8m5.0m5.8m7.3m7.9m8.5m8.8m9.3m

R&D expense

972.1k1.2m1.5m1.3m1.0m1.3m1.2m756.8k590.3k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

5.0m1.9m2.6m2.6m2.4m4.0m3.3m3.1m2.8m2.7m4.0m5.6m4.7m6.3m6.6m6.2m6.9m7.7m6.5m6.5m7.1m7.1m8.2m8.1m8.9m9.4m9.7m3.9m

General and administrative expense

1.4m1.2m1.1m1.1m1.4m1.6m1.2m1.1m1.2m1.5m1.8m1.8m1.7m2.2m1.9m1.8m2.4m2.3m2.2m2.1m2.0m2.2m2.9m1.7m2.0m3.2m4.0m

R&D expense

270.8k224.2k249.6k404.3k293.2k294.9k470.0k346.8k382.7k286.3k239.5k256.7k258.8k248.5k444.5k312.9k254.8k337.7k356.8k195.2k211.8k162.6k149.5k161.3k143.2k122.0k160.5k

Operating expense total

1.7m1.5m1.3m1.6m1.7m1.9m1.7m1.4m1.6m1.8m2.0m2.1m2.0m2.4m2.3m2.2m2.7m2.7m2.5m2.3m2.2m2.4m3.1m1.9m2.1m3.3m4.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.2m3.4m5.6m9.8m5.1m4.8m7.3m13.2m5.0m

Accounts Receivable

3.2m5.1m5.0m3.0m2.5m3.8m4.7m16.5m19.1m

Prepaid Expenses

98.2k149.7k326.5k210.8k383.8k623.5k646.7k966.5k

Inventories

624.3k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.0m3.8m5.8m3.8m3.8m7.2m4.0m4.6m8.9m8.8m9.7m10.7m8.5m7.5m9.5m7.0m4.7m9.0m6.0m6.4m12.6m13.0m13.4m17.6m14.0m12.8m19.1m16.9m

Accounts Receivable

877.4k1.7m1.8m2.8m3.2m2.9m3.9m5.0m1.9m2.0m3.1m3.7m3.0m4.2m3.8m4.3m3.8m4.9m4.7m4.7m19.2m12.9m14.5m16.5m16.7m17.8m17.8m11.7m

Prepaid Expenses

151.4k122.1k167.3k219.5k161.2k363.9k411.1k444.4k327.9k291.4k382.7k236.7k469.0k258.1k467.1k730.8k554.4k583.6k800.5k673.1k580.9k837.0k802.0k604.4k1.0m836.7k898.6k1.3m

Current Assets

12.9m12.3m14.1m12.7m13.1m15.6m16.4m17.0m19.5m20.3m21.8m29.0m32.7m37.5m48.2m50.6m55.4m55.2m58.4m61.6m82.7m81.4m87.7m101.6m103.0m101.4m122.9m112.1m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

6.6m3.0m5.3m4.6m9.6m11.4m11.3m20.1m24.5m

Depreciation and Amortization

50.7k64.2k64.3k247.1k933.0k1.7m2.2m2.4m314.2k

Accounts Payable

(3.0m)(242.2k)121.4k(90.6k)67.3k127.6k195.3k325.6k(802.5k)

Cash From Operating Activities

(687.6k)2.4m5.1m6.1m10.6m16.4m13.2m17.7m22.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

6.3m6.5m742.4k1.4m1.9m1.4m2.4m3.6m754.0k1.3m2.7m2.3m4.1m7.0m2.8m5.4m8.5m3.3m6.0m8.7m4.0m8.3m13.9m4.4m10.8m17.1m4.5m4.6m

Depreciation and Amortization

21.2k32.3k12.9k29.0k43.5k16.1k32.2k96.2k89.8k176.6k94.0k172.6k319.6k647.1k414.7k816.1k1.2m545.1k1.1m1.6m699.7k1.4m2.0m153.3k150.6k202.9k22.2k45.9k

Accounts Payable

(1.9m)(2.8m)1.8m97.4k15.6k253.1k147.7k86.2k91.4k(66.5k)(303.2k)239.9k287.7k107.4k26.7k(23.6k)380.9k422.8k423.8k46.6k308.2k118.7k(356.5k)146.1k(1.1m)(921.4k)630.1k1.1m

Cash From Operating Activities

2.3m758.1k4.1m2.4m2.6m3.9m3.9m3.4m3.9m3.4m4.0m2.0m4.5m6.2m7.4m9.4m14.8m3.3m6.3m9.4m(876.3k)8.1m12.3m6.0m9.8m14.5m8.2m14.8m
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

BioSpecifics Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

Learn more about our premium products
SecurityScorecard logo

BioSpecifics Technologies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

BioSpecifics Technologies Online and Social Media Presence

BioSpecifics Technologies's Trends

Embed Graph

BioSpecifics Technologies News and Updates

November 18, 2020

BioSpecifics Merger Investigation: Halper Sadeh LLP Encourages BioSpecifics Technologies Corp. Shareholders to Contact the Firm – BSTC

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors for possible breaches of fiduciary duty and other violations of the federal securities laws conce…
November 10, 2020

Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout

WILMINGTON, Del., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GM: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be …
October 19, 2020

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BioSpecifics Technologies Corp. Buyout

WILMINGTON, DE., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be …
November 15, 2018

BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development

LYNBROOK, N.Y., Nov. 15, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...
November 09, 2018

BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results

LYNBROOK, N.Y., Nov. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...
October 31, 2018

BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids

LYNBROOK, N.Y., Oct. 31, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...
Show more

BioSpecifics Technologies Blogs

November 08, 2019

BioSpecifics Reports Third Quarter 2019 Financial and Operating Results

- 15% year-over-year increase in royalty revenues for XIAFLEX®
October 23, 2019

Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors

October 10, 2019

BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

August 09, 2019

BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results

- 13% year-over-year increase in royalty revenues for XIAFLEX® -
May 23, 2019

BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program

May 10, 2019

BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results

- 14% year-over-year increase for BioSpecifics first quarter royalty revenues for XIAFLEX -
Show more

 BioSpecifics Technologies Frequently Asked Questions

  • When was BioSpecifics Technologies founded?

    BioSpecifics Technologies was founded in 1957.

  • Who are BioSpecifics Technologies key executives?

    BioSpecifics Technologies's key executives are Joseph Truitt, Mike Sherman and Alex Monteith.

  • How many employees does BioSpecifics Technologies have?

    BioSpecifics Technologies has 7 employees.

  • What is BioSpecifics Technologies revenue?

    Latest BioSpecifics Technologies annual revenue is $38.2 m.

  • What is BioSpecifics Technologies revenue per employee?

    Latest BioSpecifics Technologies revenue per employee is $5.5 m.

  • Who are BioSpecifics Technologies competitors?

    Competitors of BioSpecifics Technologies include Nordic Nanovector, Abliva and ViewPoint Therapeutics.

  • Where is BioSpecifics Technologies headquarters?

    BioSpecifics Technologies headquarters is located at 35 Wilbur St, Lynbrook.

  • Where are BioSpecifics Technologies offices?

    BioSpecifics Technologies has offices in Lynbrook and Wilmington.

  • How many offices does BioSpecifics Technologies have?

    BioSpecifics Technologies has 2 offices.